tau

Biogen defends anti-tau drug after stock slide

Biogen’s stock was down 8.4% when the call began, largely due to confusion surrounding the strong performance of the lowest dose in the phase 2 study.

Darren Incorvaia Jul 14, 2026 2:00pm

AAIC: Biogen bolsters hopes for pivotal anti-tau push

Jul 14, 2026 9:15am

positive negative up down good bad mixed

Biogen advances Alzheimer’s tau program despite midphase miss

May 14, 2026 8:35am

Oligomerix small molecule tamps down tau tangles in mice

Mar 14, 2025 12:30pm

arrow back backwards u-turn turn around reverse

Roche tosses out $120M tau prospect, returning rights to UCB

Oct 22, 2024 8:30am

Potential new Alzheimer's drugs target tangles of tau

Sep 19, 2024 2:42pm